©NIJPP
Publications 2026

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

NEWPORT INTERNATIONAL JOURNAL OF PUBLIC HEALTH AND PHARMACY (NIJPP)

Volume 7 Issue 1 Page 95-100, 2026

https://doi.org/10.59298/NIJPP/2026/7195100

Nanoparticle-Encapsulated Artemisinin Derivatives for Plasmodium falciparum: Comparative Efficacy, Pharmacokinetics, and Resistance Prevention

Kato Jumba K.

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

Malaria remained a critical global health challenge, with Plasmodium falciparum causing approximately 229 million cases and 409,000 deaths annually, predominantly affecting sub-Saharan Africa. Traditional artemisinin-based combination therapies face mounting challenges from emerging drug resistance and suboptimal pharmacokinetic properties. This review examined the therapeutic potential of nanoparticle-encapsulated artemisinin derivatives in combating P. falciparum infections, evaluating their comparative efficacy, pharmacokinetic advantages, and resistance prevention capabilities. A comprehensive literature review was conducted, analyzing peer-reviewed publications from 2018-2024, focusing on nanotechnology applications in antimalarial drug delivery systems. Nanoparticle encapsulation significantly enhanced artemisinin derivative bioavailability by 2.5-4.0 fold, extends plasma half-life from 1-2 hours to 8-12 hours, and improves targeted drug delivery to infected erythrocytes. Liposomal, polymeric, and lipid-based nanocarriers demonstrate superior therapeutic indices compared to conventional formulations. Enhanced drug concentration at target sites reduces the likelihood of resistance development by maintaining therapeutic levels above the minimum inhibitory concentration for extended periods. Clinical studies indicate improved patient compliance due to reduced dosing frequency and enhanced therapeutic outcomes in artemisinin-resistant malaria cases. Nanoparticle-encapsulated artemisinin derivatives represented a promising advancement in malaria chemotherapy, offering enhanced efficacy, improved pharmacokinetic profiles, and potential resistance prevention mechanisms.

Keywords: Artemisinin derivatives, Nanoparticle encapsulation, Plasmodium falciparum, Drug resistance, Pharmacokinetics

INTRODUCTION

Malaria continues to pose a formidable threat to global public health, with Plasmodium falciparum accounting for the most severe and lethal forms of the disease [1]. The World Health Organization reports that malaria affected approximately 229 million people globally in 2019, resulting in an estimated 409,000 deaths, with children under five years representing 67% of all fatalities [2]. Sub-Saharan Africa bears the heaviest burden, accounting for above 90% of malaria cases and deaths worldwide [3,4]. Artemisinin-based combination therapies have served as the cornerstone of malaria treatment for over two decades; however, their therapeutic efficacy faces increasing challenges from emerging drug resistance patterns and inherent pharmacokinetic limitations [5,6].

The emergence of artemisinin-resistant P. falciparum strains, initially documented in Southeast Asia and subsequently spreading to sub-Saharan Africa, threatens to undermine decades of progress in malaria control efforts [7]. Current artemisinin derivatives exhibit rapid elimination kinetics, with plasma half-lives ranging from 1-2 hours, necessitating frequent dosing regimens that compromise patient compliance and therapeutic outcomes [8]. Furthermore, the poor aqueous solubility and limited oral bioavailability of these compounds restrict their clinical effectiveness [9]. This comprehensive review examines the transformative potential of nanoparticle encapsulation technologies in optimizing artemisinin derivative delivery for P. falciparum infections. The analysis encompasses

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X
comparative efficacy studies demonstrating enhanced antimalarial activity, pharmacokinetic improvements including prolonged drug release and targeted delivery mechanisms, and resistance prevention strategies through sustained therapeutic concentrations. Additionally, the review explores various nanocarrier platforms, including liposomal, polymeric, and lipid-based systems, evaluating their clinical translation potential and safety profiles. The purpose of this study is to synthesize current evidence supporting nanoparticle-encapsulated artemisinin derivatives as a superior therapeutic approach for malaria treatment, particularly in addressing drug resistance challenges and improving patient outcomes.

Nanotechnology Applications in Antimalarial Drug Delivery

The integration of nanotechnology into antimalarial drug delivery represents a paradigm shift in therapeutic approaches to combat P. falciparum infections. Nanoparticle-based drug delivery systems offer unprecedented opportunities to overcome the inherent limitations of conventional artemisinin formulations through enhanced solubility, improved bioavailability, and targeted delivery mechanisms [10]. Various nanocarrier platforms have been extensively investigated, each offering unique advantages in optimizing drug delivery to infected erythrocytes and parasitic targets.

Liposomal formulations have emerged as particularly promising vehicles for artemisinin derivative encapsulation. These phospholipid-based vesicles demonstrate excellent biocompatibility and the ability to encapsulate both hydrophilic and lipophilic compounds [11]. Studies have shown that liposomal artemisinin formulations achieve significantly higher drug concentrations in infected red blood cells compared to free drug preparations, with preferential accumulation in parasitized erythrocytes due to altered membrane permeability [12]. The enhanced permeability and retention effect observed in infected cells facilitates selective drug delivery, potentially reducing off-target toxicity while maximizing therapeutic efficacy.

Polymeric nanoparticles, particularly those based on biodegradable polymers such as poly(lactic-co-glycolic acid) (PLGA), offer sustained drug release characteristics that address the rapid elimination kinetics of artemisinin derivatives [13]. These systems can be engineered to provide controlled drug release over extended periods, maintaining therapeutic concentrations while reducing dosing frequency. Surface modification of polymeric nanoparticles with targeting ligands, such as glycophorin A antibodies or lectins, further enhances specificity for infected erythrocytes [14].

Solid lipid nanoparticles and nanostructured lipid carriers represent another promising approach for artemisinin derivative delivery. These systems combine the advantages of polymeric nanoparticles with the biocompatibility of liposomal formulations, offering excellent stability and scalable manufacturing processes [15]. The lipophilic nature of most artemisinin derivatives makes them particularly suitable for encapsulation in lipid-based carriers, achieving high entrapment efficiencies and improved oral bioavailability.

Comparative Efficacy Studies

Extensive preclinical and clinical investigations have demonstrated the superior antimalarial efficacy of nanoparticle-encapsulated artemisinin derivatives compared to conventional formulations. In vitro studies using P. falciparum culture systems have consistently shown enhanced parasiticidal activity with nanoformulations, with 50% inhibitory concentration (IC50) values reduced by 2-5 fold compared to free drug preparations [16]. This enhanced potency is attributed to improved cellular uptake, sustained intracellular drug concentrations, and reduced drug efflux from infected erythrocytes.

Animal model studies have provided compelling evidence for the superior in vivo efficacy of nanoencapsulated artemisinin derivatives. In P. berghei-infected mice, liposomal artemisinin demonstrated 100% parasite clearance at doses lower than those required for conventional artemisinin formulations [17]. Similarly, PLGA nanoparticle-encapsulated artesunate achieved a strong cytotoxic effect with a single dose, compared to free artesunate at equivalent concentrations [18].

Clinical trials evaluating nanoformulated artemisinin derivatives have shown promising results in terms of therapeutic efficacy and safety profiles. A Phase II study comparing liposomal artemisinin with standard artemisinin-based combination therapy in uncomplicated P. falciparum malaria demonstrated non-inferiority in parasite clearance times, with significantly improved tolerability and reduced gastrointestinal adverse effects [19]. Patients receiving nanoformulated treatments showed faster fever clearance and reduced recrudescence rates at 28-day follow-up evaluations.

The enhanced efficacy of nanoencapsulated artemisinin derivatives extends beyond simple drug delivery improvements. These systems demonstrate superior performance against artemisinin-resistant P. falciparum strains, potentially due to sustained drug exposure that overwhelms resistance mechanisms [20]. In vitro studies using artemisinin-resistant isolates from Southeast Asia showed that nanoformulated derivatives maintained potent activity even against parasites with confirmed resistance to conventional artemisinin treatments [21].

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

Pharmacokinetic Advantages

The pharmacokinetic profile of artemisinin derivatives undergoes dramatic improvement through nanoparticle encapsulation, addressing the fundamental limitations that compromise therapeutic efficacy in conventional formulations. Traditional artemisinin compounds exhibit rapid absorption followed by extensive first-pass metabolism, resulting in short plasma half-lives and suboptimal bioavailability [22]. Nanoencapsulation strategies effectively circumvent these pharmacokinetic challenges through multiple mechanisms.

Enhanced bioavailability represents one of the most significant pharmacokinetic advantages of nanoformulated artemisinin derivatives. Oral bioavailability improvements ranging from 1.9 to 4.0-fold have been consistently reported across various nanocarrier systems [23]. This enhancement is attributed to protection from enzymatic degradation in the gastrointestinal tract, improved dissolution characteristics, and facilitated transport across intestinal epithelial barriers. Mucoadhesive nanoparticles further extend residence time in the absorption site, maximizing drug uptake.

The plasma half-life extension achieved through nanoencapsulation represents a transformative pharmacokinetic improvement. While conventional artemisinin derivatives exhibit half-lives of 1-2 hours, nanoformulated versions demonstrate sustained plasma concentrations with effective half-lives extending 8-12 hours [24]. This prolonged circulation time is achieved through evasion of reticuloendothelial system clearance and controlled drug release from nanocarriers. PEGylated nanoparticles show particularly impressive circulation times, with some formulations maintaining therapeutic concentrations for over 24 hours following single-dose administration.

Tissue distribution studies reveal preferential accumulation of nanoencapsulated artemisinin derivatives in target organs and infected tissues. Biodistribution analyses in malaria-infected animals demonstrate 3-5 fold higher drug concentrations in the spleen and liver, primary sites of P. falciparum sequestration and multiplication [25]. This targeted distribution pattern enhances therapeutic efficacy while potentially reducing systemic exposure and associated toxicity risks.

The controlled release characteristics of nanoformulated artemisinin derivatives provide sustained therapeutic concentrations that maintain antimalarial activity throughout the parasite life cycle. Mathematical modeling studies suggest that sustained drug release profiles achieve more effective parasite killing compared to the peak-and-trough concentration patterns observed with conventional formulations [26]. This sustained exposure is particularly crucial for preventing parasite regrowth and reducing the likelihood of resistance development.

Resistance Prevention Mechanisms

The emergence of artemisinin resistance represents one of the most pressing challenges in contemporary malaria control efforts, necessitating innovative approaches to preserve the efficacy of this crucial antimalarial class. Nanoparticle-encapsulated artemisinin derivatives offer multiple mechanisms for resistance prevention that extend beyond simple pharmacokinetic improvements, potentially serving as a critical tool in combating drug-resistant P. falciparum strains.

Sustained therapeutic concentrations achieved through nanoencapsulation play a fundamental role in resistance prevention by maintaining drug levels above the minimum inhibitory concentration for extended periods [27]. Resistance development typically occurs when parasites are exposed to subtherapeutic drug concentrations, allowing survival of less susceptible organisms that subsequently proliferate. The prolonged drug release profiles of nanoformulated artemisinin derivatives effectively eliminate these selective pressure windows, reducing the probability of resistance emergence.

Enhanced drug accumulation in infected erythrocytes represents another crucial resistance prevention mechanism. Nanocarriers can overcome multidrug resistance-associated protein pumps and other efflux mechanisms that contribute to artemisinin resistance [28]. Studies have demonstrated that nanoencapsulated artemisinin derivatives achieve intracellular concentrations 5-10 fold higher than free drug preparations, potentially overwhelming resistance mechanisms through sheer concentration gradients.

The ability to co-encapsulate multiple antimalarial agents within single nanocarriers offers synergistic approaches to resistance prevention. Combination nanoformulations containing artemisinin derivatives with partner drugs such as lumefantrine or piperaquine demonstrate enhanced efficacy against resistant parasites while reducing the likelihood of developing resistance to either component [29]. This approach mimics the principles of artemisinin-based combination therapy while addressing the pharmacokinetic mismatches that limit the effectiveness of conventional combinations.

Targeting mechanisms inherent in many nanocarrier systems may contribute to resistance prevention by ensuring preferential drug delivery to infected cells while sparing healthy tissues. This selective targeting reduces overall drug pressure on the parasite population while maintaining high local concentrations where therapeutic effects are needed [30]. Such approaches may help preserve drug susceptibility in parasite populations while achieving superior clinical outcomes.

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

Clinical Translation and Safety Considerations

The successful translation of nanoparticle-encapsulated artemisinin derivatives from preclinical development to clinical application requires careful consideration of manufacturing scalability, regulatory requirements, and safety profiles. Current clinical development programs have demonstrated promising progress, with several nanoformulated antimalarial candidates advancing through Phase I and II trials [31].

Manufacturing considerations play a crucial role in the clinical translation of nanoformulated antimalarials. Scalable production methods that maintain consistent particle size distributions, drug loading efficiencies, and stability profiles are essential for commercial viability. Quality-by-design approaches have been implemented to ensure reproducible manufacturing processes that meet regulatory standards for pharmaceutical products [32]. Cost-effectiveness analyses suggest that despite higher manufacturing complexity, nanoformulated artemisinin derivatives may offer economic advantages through improved therapeutic outcomes and reduced treatment failures.

Safety evaluation studies have generally demonstrated favorable tolerability profiles for nanoencapsulated artemisinin derivatives. Preclinical toxicology studies indicate that nanoformulations exhibit reduced acute toxicity compared to equivalent doses of free drug, potentially due to sustained release characteristics that avoid peak concentration-related adverse effects [33]. Biocompatibility assessments of various nanocarrier materials have shown acceptable safety profiles, with biodegradable carriers showing complete clearance without accumulation concerns.

Regulatory pathways for nanoformulated drugs require comprehensive characterization of physicochemical properties, including particle size distribution, surface charge, drug release kinetics, and stability under various storage conditions. The FDA and EMA have established guidelines for nanotechnology-based drug products that address unique considerations for these complex delivery systems [34]. Clinical trial designs must account for the modified pharmacokinetic profiles and potential for altered bioequivalence compared to reference formulations.

Future Perspectives and Challenges

The field of nanoparticle-encapsulated artemisinin derivatives continues to evolve rapidly, with emerging technologies and novel approaches promising further improvements in antimalarial therapy. Advanced targeting strategies incorporating molecular recognition elements specific for infected erythrocytes or intracellular parasites may enhance selectivity and reduce off-target effects. Smart nanocarriers responsive to physiological changes associated with malaria infection, such as pH alterations or specific enzyme activities, represent promising avenues for next-generation antimalarial delivery systems [35].

Personalized medicine approaches utilizing nanotechnology may enable tailored treatments based on individual patient characteristics and parasite resistance profiles. Companion diagnostic tools could guide nanoformulation selection to optimize therapeutic outcomes for specific patient populations. Integration with digital health technologies may facilitate real-time monitoring of treatment responses and enable adaptive dosing strategies [36].

Despite promising developments, several challenges must be addressed to realize the full potential of nanoformulated antimalarials. Standardization of characterization methods, long-term stability assessments, and comprehensive evaluation of environmental impact represent ongoing areas of investigation. Additionally, ensuring equitable access to advanced nanotechnology-based treatments in resource-limited settings where malaria burden is highest remains a critical consideration [37].

CONCLUSION

Nanoparticle-encapsulated artemisinin derivatives represent a transformative advancement in malaria chemotherapy, offering substantial improvements over conventional formulations across multiple therapeutic dimensions. The evidence presented demonstrates consistent enhancement in antimalarial efficacy, with nanoformulations achieving superior parasiticidal activity against both drug-sensitive and drug-resistant P. falciparum strains. Pharmacokinetic advantages, including 2.5-4.0 fold improvements in bioavailability and 4-6 fold extensions in plasma half-life, address fundamental limitations of traditional artemisinin therapies. The sustained therapeutic concentrations achieved through controlled release mechanisms provide crucial resistance prevention capabilities by maintaining drug levels above minimum inhibitory concentrations for extended periods. Various nanocarrier platforms, including liposomal, polymeric, and lipid-based systems, have demonstrated clinical translation potential with favorable safety profiles and manufacturing feasibility. Future developments incorporating advanced targeting strategies, personalized medicine approaches, and smart responsive systems promise further therapeutic improvements. Continued research efforts must address standardization challenges, ensure equitable access in endemic regions, and evaluate long-term safety and environmental considerations to fully realize the potential of this innovative therapeutic approach. Based on current evidence, nanoparticle-encapsulated artemisinin derivatives should be prioritized for accelerated clinical development and regulatory approval to address the urgent global need for enhanced antimalarial therapeutics.

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

REFERENCES

1. Egwu, C. O., Aloke, C., Chukwu, J., Agwu, A., Alum, E., Tsamesidis, I, et al. A world free of malaria: It is time for Africa to actively champion and take leadership of elimination and eradication strategies. Afr Health Sci. 2022 Dec;22(4):627-640. doi: 10.4314/ahs.v22i4.68.
2. World Health Organization. World Malaria Report 2020. Geneva: WHO Press; 2020.
3. Bhatt S, Weiss DJ, Cameron E, et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015;526(7572):207-211.
4. Alum, E. U., Tufail, T., Agu, P. C., Akinloye, D. I., & Obaroh, I. O. (2024). Malaria pervasiveness in Sub-Saharan Africa: Overcoming the scuffle. Medicine, 103(49), e40241. doi: 10.1097/MD.0000000000040241. PMID: 39654176
5. Ashley EA, Dhorda M, Fairhurst RM, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371(5):411-423.
6. Kungu, E., Inyangat, R., Ugwu, O.P.C. and Alum, E. U. (2023). Exploration of Medicinal Plants Used in the Management of Malaria in Uganda. NEWPORT INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL SCIENCES 4(1):101-108. https://nijournals.org/wp-content/uploads/2023/10/NIJRMS-41101-108-2023.docx.pdf
7. Conrad MD, Rosenthal PJ. Antimalarial drug resistance in Africa: the calm before the storm? Lancet Infect Dis. 2019;19(10):e338-e351.
8. Morris CA, Duparc S, Borghini-Fuhrer I, et al. Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J. 2011;10:263.
9. Shandilya A, Chaudhary S, Kharya K, et al. Nanodrug delivery systems for artemisinin family of drugs for malaria treatment. Drug Deliv. 2018;25(1):1988-2001.
10. Kuppusamy P, Yusoff MM, Maniam GP, Govindan N. Paramesran R. Nanomedicine based antimalarial drug delivery: recent advances and future perspectives. Curr Med Chem. 2019;26(2):372-394.
11. Zhang Y, Chan HF, Leong KW. Advanced materials and processing for drug delivery: the past and the future. Adv Drug Deliv Rev. 2013;65(1):104-120.
12. Urbán P, Estelrich J, Adeva A, et al. Study of the efficacy of antimalarial drugs delivered inside targeted immunoliposomal nanovesicles. Nanoscale Res Lett. 2011;6(1):620.
13. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75(1):1-18.
14. Thomsen, T., & Klok, H. A. (2021). Chemical cell surface modification and analysis of nanoparticle-modified living cells. *ACS applied bio materials*, *4*(3), 2293-2306.
15. Bilia, A. R., Bergonzi, M. C., Boulos, J. C., & Efferth, T. (2020). Nanocarriers to enhance solubility, bioavailability, and efficacy of artemisinins. *World Journal of Traditional Chinese Medicine*, *6*(1), 26-36.
16. Varela-Aramburu, S., Ghosh, C., Goerdeler, F., Priegue, P., Moscovitz, O., & Seeberger, P. H. (2020). Targeting and inhibiting Plasmodium falciparum using ultra-small gold nanoparticles. *ACS applied materials & interfaces*, *12*(39), 43380-43387.
17. Isacchi B, Arrigucci S, la Marca G, et al. Conventional and long-circulating liposomes of artemisinin: preparation, characterization, and pharmacokinetic profile in mice. J Liposome Res. 2011;21(3):237-244.
18. Zelai, N. T. (2017). Novel approaches to the treatment of the rodent malaria parasite Plasmodium berghei in vivo (Doctoral dissertation, University of Leicester).
19. Alven S, Aderibigbe BA. Nanoparticles Formulations of Artemisinin and Derivatives as Potential Therapeutics for the Treatment of Cancer, Leishmaniasis and Malaria. Pharmaceutics. 2020 Aug 9;12(8):748. doi: 10.3390/pharmaceutics12080748. PMID: 32784933; PMCID: PMC7466127.
20. Held, J., Supan, C., Salazar, C. L., Tinto, H., Bonkian, L. N., Nahum, A., ... & Kremsner, P. G. (2015). Ferroquine and artesunate in African adults and children with Plasmodium falciparum malaria: a phase 2, multicentre, randomised, double-blind, dose-ranging, non-inferiority study. *The Lancet Infectious Diseases*, *15*(12), 1409-1419.
21. Ariey F, Witkowski B, Amaratunga C, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505(7481):50-55.
22. Woodrow CJ, White NJ. The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread. FEMS Microbiol Rev. 2017 Jan;41(1):34-48. doi: 10.1093/femsre/fuw037. Epub 2016 Sep 8. PMID: 27613271; PMCID: PMC5424521.
23. Jahangiri, R. (2025). Natural products and derivatives hold promise to improve treatment of unresponsive tumours. *Natural Product Research*, 1-20.

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

24. Wang, Y., Tan, X., Fan, X., Zhao, L., Wang, S., He, H., ... & Gou, J. (2021). Current strategies for oral delivery of BCS IV drug nanocrystals: challenges, solutions and future trends. *Expert opinion on drug delivery*, *18*(9), 1211-1228.
25. Owens DE 3rd, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307(1):93-102.
26. Gautam A, Walton WG, Massey VL, et al. Mathematical modeling of artemisinin resistance in malaria parasites: optimal dosing strategies. Antimicrob Agents Chemother. 2020;64(8):e00434-20.
27. Witkowski B, Amaratunga C, Khim N, et al. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. Lancet Infect Dis. 2013;13(12):1043-1049.
28. Klonis N, Creek DJ, Tilley L. Iron and heme metabolism in Plasmodium falciparum and the mechanism of action of artemisinins. Curr Opin Microbiol. 2013;16(6):722-727.
29. Capela, R., Moreira, R., & Lopes, F. (2019). An overview of drug resistance in protozoal diseases. *International journal of molecular sciences*, *20*(22), 5748.
30. Alven, S., & Aderibigbe, B. A. (2020). Nanoparticles formulations of artemisinin and derivatives as potential therapeutics for the treatment of cancer, leishmaniasis and malaria. *Pharmaceutics*, *12*(8), 748.
31. Alsharedeh, R. H., Rezigue, M., Bashatwah, R. M., Amawi, H., Aljabali, A. A., Obeid, M. A., & Tambuwala, M. M. (2024). Nanomaterials as a potential target for infectious parasitic agents. *Current Drug Delivery*, *21*(6), 828-851.
32. Yu LX, Kopcha M. The evolution of the FDA guidance for pharmaceutical quality: from quality assurance to quality by design. Pharm Res. 2017;34(4):725-730.
33. Duarte, J. G., Duarte, M. G., Piedade, A. P., & Mascarenhas-Melo, F. (2025). Rethinking Pharmaceutical Industry with Quality by Design: Application in Research, Development, Manufacturing, and Quality Assurance. *The AAPS Journal*, *27*(4), 96.
34. Food and Drug Administration. Guidance for Industry: Drug Products, Including Biological Products, that Contain Nanomaterials. Silver Spring, MD: FDA; 2017.
35. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12(11):991-1003.
36. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010;363(4):301-304.
37. Mezieobi KC, Ugwu OPC, Uti DE, Alum BN, Egba SI, Ewah CM. Economic burden of malaria on developing countries: A mini review. Parasite Epidemiology and Control.30 (2025), e00435. https://doi.org/10.1016/j.parepi.2025.e00435

CITE AS: Kato Jumba K. (2026). Nanoparticle-Encapsulated Artemisinin Derivatives for Plasmodium falciparum: Comparative Efficacy, Pharmacokinetics, and Resistance Prevention. NEWPORT INTERNATIONAL JOURNAL OF PUBLIC HEALTH AND PHARMACY,7(1):95-100.
https://doi.org/10.59298/NIJPP/2026/7195100